GLP-1 and Hair Loss

Hair shedding has been reported during treatment with semaglutide, tirzepatide and other medications commonly grouped under the “GLP-1” label. However, researchers have not established a single cause.

Rapid or substantial weight loss, sharply reduced calorie or protein intake, gastrointestinal symptoms, nutritional deficiency and the physical stress of major metabolic change can all trigger telogen effluvium. At the same time, clinical trials and observational studies have found more hair-loss reports among some people using these medications, so a medication-specific contribution cannot yet be excluded.

For most affected patients, the reported pattern is nonscarring hair loss. This means the follicles remain present and regrowth may be possible. However, not every case is temporary telogen effluvium, and persistent, patterned, patchy or inflammatory hair loss requires proper assessment.

Image note: This original image has been preserved, but the current file appears to render incorrectly, with a large gray area obscuring part of the design. It should be re-exported and replaced at the same WordPress URL if possible.

Medical note: Do not stop or change a prescribed GLP-1 or GIP/GLP-1 medication because of hair shedding without speaking with the clinician managing your treatment. These medications may provide important metabolic, cardiovascular and diabetes-related benefits. The cause of the shedding should be investigated before treatment decisions are made.

Key Takeaways

• Hair loss is a documented adverse event in some weight-management trials. It occurred more frequently with semaglutide and tirzepatide than with placebo in the trials summarized in current prescribing information.
• The cause is not fully established. Rapid weight loss, reduced food intake, nutrient deficiency and telogen effluvium are plausible explanations, but a direct medication contribution cannot be excluded.
• The absolute risk appears relatively low. Most people taking these medications do not develop clinically significant hair loss.
• Shedding may be delayed. Telogen effluvium commonly becomes noticeable several weeks to a few months after the triggering event.
• Diffuse shedding and pattern hair loss can overlap. A temporary shed can reveal previously subtle androgenetic alopecia.
• Testing should be individualized. There is no single mandatory “GLP-1 hair-loss panel” for every patient.
• Do not start supplements blindly. Iron, zinc and other nutrients can be harmful in excess and should be used when dietary assessment or appropriate testing identifies a need.
• Do not stop prescribed medication on your own. Review the benefits, risks, weight-loss rate, intake and alternative explanations with the prescribing clinician.

What Are GLP-1 Medications?

Glucagon-like peptide-1 receptor agonists imitate some of the activity of the naturally occurring GLP-1 hormone. Depending on the medication and indication, they can improve glucose-dependent insulin secretion, reduce appetite, slow gastric emptying and support weight reduction.

Examples include semaglutide, marketed under names such as Ozempic, Wegovy and Rybelsus for different indications and formulations.

Tirzepatide, marketed as Mounjaro or Zepbound depending on the indication, is technically a dual GIP and GLP-1 receptor agonist, rather than a GLP-1-only medication. It is nevertheless commonly included in public discussions about “GLP-1 medications.”

These medications are prescribed for different medical purposes. Brand, dose, formulation and indication matter when interpreting adverse-event data.

Do GLP-1 Medications Cause Hair Loss?

The most accurate answer is: an association exists, but the mechanism and degree of direct causation remain uncertain.

Hair loss was reported more frequently in several obesity-treatment trials involving semaglutide and tirzepatide. Current prescribing information describes the reported hair loss as being associated with weight reduction.^{1, 2}

The 2026 observational study found that the absolute rates remained low, despite a higher relative risk among GLP-1 receptor agonist users. The evidence therefore supports informed monitoring, not the conclusion that severe hair loss is inevitable.³

Is the Medication Directly Damaging Hair Follicles?

There is currently no strong evidence that semaglutide or tirzepatide routinely destroys hair follicles or causes scarring alopecia.

However, it is also too early to state that the medications themselves play no direct role. Clinical trials were not designed primarily to diagnose hair-loss subtypes, and observational studies cannot completely separate several overlapping factors:

• The medication.
• The amount and speed of weight loss.
• Reduced calorie and protein intake.
• Nausea, vomiting or limited food variety.
• Pre-existing iron or other nutritional deficiency.
• Thyroid disease or another medical condition.
• Pre-existing androgenetic alopecia.
• Other medication changes, illness or psychological stress.

A 2026 systematic review concluded that evidence is accumulating for an association, particularly with semaglutide and tirzepatide, but prospective research is still needed to establish causality and identify the mechanism.⁴

Telogen Effluvium During Weight Loss

Telogen effluvium is a nonscarring shedding disorder that can follow a major physiological, nutritional, hormonal or medication-related trigger.

The trigger causes more follicles than usual to leave the active growth phase. Those hairs are not released immediately. Increased shedding often becomes noticeable around two to four months later, although timing varies.

Potential triggers during GLP-1-based treatment include:

• Rapid or substantial weight reduction.
• A sharp decrease in calorie intake.
• Insufficient protein intake.
• Persistent nausea or vomiting.
• Limited dietary variety.
• Iron deficiency or another clinically relevant deficiency.
• Illness, surgery, fever or another simultaneous stressor.
• Starting, stopping or changing another medication.

The delayed timing can make cause and effect difficult to recognize. A person may start shedding after their appetite, weight-loss rate or gastrointestinal symptoms have already changed.

Telogen effluvium is delayed because affected hairs remain in the follicle for a period before they are released. The exact timing differs among individuals.

What Does Telogen Effluvium Look Like?

Telogen effluvium usually causes increased shedding across much of the scalp rather than one isolated bald patch.

Common observations include:

• More hair in the shower or sink.
• More hair in a brush or comb.
• Hairs coming away when washing or gently handling the hair.
• A smaller ponytail circumference.
• General loss of volume.
• Greater scalp visibility without a clearly defined bald patch.

The follicles remain present in uncomplicated telogen effluvium. Once the trigger resolves, shedding can gradually settle and new growth can resume. Recovery is not immediate because the hair cycle moves slowly.

Telogen Effluvium vs Pattern Hair Loss

A temporary shed can occur at the same time as androgenetic alopecia. In some cases, diffuse shedding makes an existing pattern more noticeable.

GLP-1 therapy has not been shown to create genetic pattern hair loss from nothing. However, weight-loss-associated shedding may expose density loss that was previously difficult to see. Some observational studies have also reported androgenetic alopecia diagnoses among GLP-1 users, although causality remains uncertain.^{4, 5}

Learn more about androgenetic alopecia.

Who May Be More Vulnerable to Shedding?

No reliable test can predict exactly who will develop hair loss during treatment. Risk may be higher when several triggers occur together.

Factors worth reviewing include:

• Rapid or substantial weight loss.
• Very low food intake.
• Difficulty meeting protein needs.
• Frequent nausea or vomiting.
• Heavy menstrual bleeding.
• Previous iron deficiency.
• Vegetarian, vegan or otherwise restrictive eating patterns.
• Recent pregnancy, surgery, illness or fever.
• Thyroid disease.
• Pre-existing pattern hair loss.
• A history of telogen effluvium.
• Use of another medication associated with shedding.

Current prescribing information also reports hair loss more often in women than men in the relevant weight-reduction trials. This observation does not prove that biological sex alone caused the difference. Menstrual blood loss, underlying iron status, hormonal factors, reporting patterns and other variables may contribute.^{1, 2}

Nutrition During GLP-1 Treatment

Hair follicles require adequate energy and amino acids to sustain growth. Sudden weight loss and reduced protein intake are recognized triggers for telogen effluvium.^{6, 7}

Nevertheless, the solution is not to take every supplement marketed for hair growth. Nutrition should be reviewed systematically.

Protein

Appetite suppression can make it difficult to meet protein needs. A prescribing clinician or registered dietitian can help determine an appropriate intake based on body size, health conditions, activity, weight-loss plan and kidney function.

Useful food sources may include eggs, fish, poultry, lean meat, dairy products, soy foods, beans, lentils, nuts and seeds. The appropriate choices depend on medical needs and dietary preferences.

Iron and Ferritin

Iron deficiency can contribute to diffuse shedding, particularly in people with heavy menstrual bleeding, restrictive diets, gastrointestinal disease or a previous history of low iron.

Ferritin is useful when interpreted alongside the complete blood count, iron studies, symptoms, inflammation and medical history. It should not be treated as a stand-alone hair-growth score, and there is no universally accepted ferritin target that guarantees regrowth.

Read more about ferritin deficiency and hair loss.

Vitamin and Mineral Testing

Testing may be considered when the history, diet or symptoms suggest a risk. Depending on the individual, a clinician may consider:

• Complete blood count.
• Ferritin and iron studies.
• Thyroid testing.
• Vitamin B12 or folate.
• Vitamin D.
• Zinc or other targeted tests.

This is not a mandatory panel for everyone. Laboratory decisions should be based on the clinical picture.

True biotin deficiency is uncommon. High-dose biotin supplements can also interfere with certain laboratory tests, including some thyroid and cardiac tests. Tell the clinician and laboratory about every supplement you take.

Should You Stop Semaglutide or Tirzepatide?

Image note: This original image has been preserved, but the file currently appears to contain a large gray area that obscures much of the design. It should be re-exported and replaced.

Do not stop, reduce or delay a prescribed dose without discussing the decision with the prescribing clinician.

Hair shedding can be upsetting, but stopping medication may not immediately stop telogen effluvium. The hair-cycle shift may already have occurred weeks or months earlier.

A safer review includes:

1. Confirming the medication, dose and timeline.
2. Reviewing the amount and pace of weight loss.
3. Assessing calorie and protein intake.
4. Discussing persistent nausea, vomiting or inability to eat adequately.
5. Reviewing other medications and recent illnesses.
6. Examining the pattern of hair loss.
7. Ordering targeted laboratory testing where clinically appropriate.
8. Balancing the medication’s benefits against the severity and likely cause of the shedding.

The prescriber may decide that no medication change is necessary. In other cases, the clinician may review dose escalation, gastrointestinal adverse effects, nutritional support or alternative treatment options. That decision is individual.

What Can You Do About GLP-1-Associated Hair Shedding?

1. Tell the Prescribing Clinician

Report the timing, severity and pattern of the shedding. Also mention changes in appetite, weight, gastrointestinal symptoms, menstrual bleeding, other medications and recent illness.

2. Avoid Extreme Restriction

Do not intensify calorie restriction simply to accelerate results. The appropriate rate of weight loss should be discussed with the clinician or dietitian managing treatment.

3. Plan Nutritionally Complete Meals

Because appetite may be unreliable, meals may need to be planned deliberately. Prioritize adequate protein and a varied diet rather than relying on hair supplements to compensate for consistently inadequate intake.

4. Correct Confirmed Deficiencies

Iron, vitamin B12, folate, vitamin D, zinc or another nutrient should be supplemented when there is a defensible dietary or medical reason. More is not automatically better.

5. Use Gentle Hair and Scalp Care

During active shedding:

• Avoid tight hairstyles that pull on the roots.
• Limit aggressive brushing and chemical processing.
• Reduce excessive heat where practical.
• Use a mild cleansing routine appropriate for the scalp.
• Do not aggressively scrub or microneedle an irritated scalp.

6. Document the Pattern

Take standardized photographs under the same lighting, angle, hairstyle and parting. Monthly photographs are often more useful than daily checking.

7. Treat a Separate Hair-Loss Condition When Appropriate

Telogen effluvium, androgenetic alopecia, alopecia areata and inflammatory or scarring alopecias require different approaches. Treatments such as minoxidil may be considered for an appropriate diagnosis, but they should not be started automatically for every temporary shed.

How Long Does the Shedding Last?

The timeline depends on the cause and whether the trigger continues.

In an uncomplicated acute telogen effluvium episode, increased shedding may continue for several months before settling. New growth then needs time to become long enough to affect visible density.

Many people will not see an obvious cosmetic recovery immediately. Visible improvement may take six months or longer, especially after a substantial shed.

Persistent shedding does not automatically mean permanent loss. However, ongoing shedding beyond six months, progressive pattern thinning or failure to recover should prompt reassessment for continuing nutritional, endocrine, medication-related or genetic factors.

When to Seek Medical or Dermatological Assessment

Arrange appropriate medical or dermatological evaluation if you experience:

• Round or irregular bald patches.
• Loss of eyebrows or eyelashes.
• Scalp redness, scale, crusting or pustules.
• Persistent burning, pain or marked tenderness.
• Shiny areas or apparent loss of follicular openings.
• Rapidly progressive pattern thinning.
• Symptoms of anemia, thyroid disease or another systemic illness.
• Persistent vomiting, dehydration or inability to maintain adequate intake.
• Shedding that continues without improvement.

These findings are not adequately explained by ordinary weight-loss-associated telogen effluvium and should not be managed with supplements alone.

Frequently Asked Questions About GLP-1s and Hair Loss

Can semaglutide cause hair loss?

Hair loss was reported more frequently with weight-management doses of semaglutide than with placebo in clinical trials. Rapid weight loss and reduced intake may contribute, but researchers have not determined whether semaglutide also has a direct effect on the hair cycle.

Can tirzepatide cause hair loss?

Hair loss was reported in approximately 4–5% of participants receiving Zepbound in pooled weight-reduction trials, compared with 1% receiving placebo. Current prescribing information says these events were associated with weight reduction. The exact mechanism remains uncertain.

Is Ozempic hair loss permanent?

Not necessarily. If the loss is acute telogen effluvium, the follicles remain present and recovery may occur after the trigger stabilizes. Persistent pattern thinning, patchy loss or inflammatory symptoms may have another cause and require assessment.

When does hair shedding start after beginning a GLP-1 medication?

Telogen effluvium commonly becomes visible around two to four months after a trigger. The relevant trigger could be starting treatment, dose escalation, rapid weight loss, reduced intake, illness or another event.

Does faster weight loss increase the risk?

Rapid or substantial weight loss is a recognized telogen-effluvium trigger. However, there is no single rate that predicts hair shedding in every person. Nutritional adequacy, health history and other triggers also matter.

Should I stop Wegovy, Ozempic, Mounjaro or Zepbound?

Do not stop prescribed medication without speaking to the clinician managing it. The clinician should review the treatment benefits, shedding pattern, weight-loss rate, diet, adverse effects and other possible causes before recommending a change.

What blood tests should be checked?

There is no universal panel. Depending on the history and symptoms, a clinician may consider a complete blood count, ferritin and iron studies, thyroid testing, vitamin B12, folate, vitamin D, zinc or other targeted tests.

Should I take biotin for GLP-1 hair loss?

Biotin is unlikely to help unless a deficiency exists, and true deficiency is uncommon. High-dose biotin can interfere with important laboratory tests. Discuss supplementation with a qualified clinician.

Can GLP-1 treatment reveal pattern hair loss?

Yes. A diffuse telogen-effluvium episode can reduce overall density and make previously subtle temple, crown or part-line thinning more visible. This does not prove that the medication created the underlying genetic condition.

Will the hair grow back?

Hair often regrows after uncomplicated telogen effluvium once the trigger resolves and adequate nutrition is restored. Recovery can take many months. Regrowth is less predictable when another condition, such as androgenetic alopecia or inflammatory hair loss, is also present.

Related Hair-Loss Guides

Conclusion

Hair loss during semaglutide or tirzepatide treatment should not be dismissed, but it should not automatically be blamed on direct follicular toxicity either.

Clinical trials and newer observational studies support an association between some GLP-1-based treatments and hair loss. Rapid weight loss, appetite suppression, inadequate protein or calorie intake, nutritional deficiency and telogen effluvium are plausible contributors. However, researchers have not yet determined whether these factors explain every case.

The appropriate response is to document the pattern, review the timeline, assess nutrition and medical risk factors, and involve the prescribing clinician. Do not stop medication or begin high-dose supplements without appropriate guidance.

Most reported cases appear to involve nonscarring loss, which means recovery may be possible. Persistent, patterned, patchy, painful or inflammatory hair loss requires a broader evaluation.

References

1. Novo Nordisk — Wegovy Prescribing Information.
2. Eli Lilly and Company — Zepbound Prescribing Information.
3. Tang H, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077.
4. Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Science Progress. 2026;109(2).
5. Herrera HO, Bordeaux JS. Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. Journal of the American Academy of Dermatology. 2026;94(6):1826–1827.
6. Yin GOC, et al. Telogen Effluvium: A Review of the Science and Current Obstacles. Journal of Dermatological Science. 2021;101(3):156–163.
7. Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatology Practical & Conceptual. 2017;7(1):1–10.
8. British Association of Dermatologists — Telogen Effluvium Patient Information.

Medical disclaimer: This article is for general educational purposes only and does not replace medical advice, diagnosis or treatment. Do not start, stop or change semaglutide, tirzepatide or another prescribed medication without speaking with the clinician managing your treatment. Hair loss may have medication-related, nutritional, endocrine, genetic, autoimmune, inflammatory, infectious or mechanical causes. Seek appropriate medical or dermatological assessment for unexplained, progressive, patchy, painful or scarring hair loss.

About the Author

Dr. Samuel Sarmiento Author

Dr. Samuel Sarmiento is a physician with a rich background in clinical medicine, public health, and research. He completed his surgical internship at the Mayo Clinic, where he gained invaluable experience in one of the world's most renowned healthcare institutions. Recognizing the need to broaden his expertise beyond clinical practice, he pursued dual master’s degrees in Public Health and Business Administration at Johns Hopkins University, followed by a postdoctoral fellowship in clinical outcomes research within the Department of Plastic Surgery. View Full Profile